表紙
市場調查報告書

競爭企業分析:癌症免疫 & 其他的疾病雙特異性抗體

Competitor Analysis: Bispecific Antibodies for Immuno-Oncology & Other Diseases

出版商 La Merie Publishing 商品編碼 890224
出版日期 內容資訊 英文 125 Pages
訂單完成後即時交付
價格
競爭企業分析:癌症免疫 & 其他的疾病雙特異性抗體 Competitor Analysis: Bispecific Antibodies for Immuno-Oncology & Other Diseases
出版日期: 2019年06月30日內容資訊: 英文 125 Pages
簡介

本報告提供癌症,發炎性、自體免疫性疾病,及心臟代謝性、感染性、神經性、眼科疾病的雙特異性治療用抗體的相關調查,各抗體的製造技術,目前R&D形勢,競爭企業的計劃等分析。

第1章 T細胞重定向雙特異性抗體

  • BCMA標的
  • CD20標的
  • CD19標的
  • CD33標的
  • CD123標的
  • PSMA標的
  • Her2標的
  • Mesothelin標的
  • CD38標的
  • EGF-R標的
  • DLL3 等

第2章 雙特異性自然殺手 (NK) 細胞重定向抗體

第3章 雙特異性T細胞接合,附條件共刺激抗體

第4章 雙特異性癌症免疫抗體

第5章 雙特異性腫瘤相關抗原 (TAA):以抗體為標的成長要素

  • Her2標的
  • VEGF標的
  • 其他TAA標的

第6章 對癌症以外的症狀的雙特異性抗體

  • 發炎性、自體免疫性疾病
  • 心臟代謝性疾病
  • 眼科疾病
  • 神經性疾病
  • 感染疾病
  • 靶向遞送
目錄
Product Code: LMCA0176

Competitor Analysis: Bispecific Antibodies for Immuno-Oncology & Other Diseases

This Competitive Intelligence report about Bispecific Antibodies for Immuno-Oncology & Other Diseases evaluates the landscape of investigational bispecific therapeutic antibodies for treatment of cancer, inflammatory & autoimmune diseaseas as well as cardiometabolic, infectious, neurologic and ophthalmic diseases as of June 2019.

At present, only two bispecific therapeutic monoclonal antibodies are on the market, one for leukemia and one for hemophilia. La Merie Publishing conducted a search for bispecific monoclonal antibodies (and some multimeric proteins) in R&D. The search identified 271 unique bispecific antibody-based constructs in active R&D (excluding discontinued developments of bispecifics). Of the 110 clinical stage bispecific antibodies, 50% are used for redirection of T-cells to a tumor target. More than 85% of the clinical stage bispecific molecules are in development for treatment of cancer. The combination of immune checkpoint inhibitor and/or activator targets is a strongly emerging use of the bispecific antibody technology. The traditonal application of bispecifics for targeting two tumor-associated antigens (or epitopes) and/or growth factors is a field with strong clinical activities, but the non-clinical pipeline is relatively empty compared with immuno-oncology bispecifics (11 vs 48 projects).

The report highlights the use of bispecific antibody technology for generation of

  • T-Cell Redirecting Bispecific Antibodies
  • Bispecific Natural Killer (NK) Cell Redirecting Antibodies
  • Bispecific T-Cell Engaging, Conditional Costimulatory Antibodies
  • Bispecific Immuno-Oncology Antibodies
  • Bispecific Tumor Associated Antigen (TAA) / Growth Factor Targeted Antibodies
  • Bispecific Antibodies for Non-Cancer Indications

The report includes a compilation of currently active projects in research and development of bispecific therapeutic antibodies in cancer and non-cancer indications. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies. The information is provided in a tabular format and fully referenced.

Table of Contents

1) T-Cell Redirecting Bispecific Antibodies

  • Targeting BCMA
  • Targeting CD20
  • Targeting CD19
  • Targeting CD33
  • Targeting CD123
  • argeting PSMA
  • Targeting Her2
  • Targeting Mesothelin
  • Targeting CD38
  • Targeting EGF-R
  • Targeting DLL3
  • Targeting Various Other Cancer Surface Antigens
  • Targeting Not Disclosed Tumor Associated Antigens
  • Targeting (Intracellular) peptide/MHC Antigens
  • Novel Bispecific T-Cell Redirecting Antibody Constructs
  • Bispecific T-Cell Redirecting Antibodies for Infectious & Other Diseases

2) Bispecific Natural Killer (NK) Cell Redirecting Antibodies

3) Bispecific T-Cell Engaging, Conditional Costimulatory Antibodies

  • Bispecific, Tumor-Targeted, Conditional 4-1BB Costimulatory Antibodies
  • Bispecific, Tumor-Targeted, Conditional CD40 Costimulatory Antibodies
  • Bispecific, Tumor-Targeted, Conditional CD28 or OX40 Costimulatory Antibodies
  • Bispecific, Dual Costimulatory Antibodies

4) Bispecific Immuno-Oncology Antibodies

  • Bispecific, Tumor-Targeted Checkpoint Inhibitor Antibodies
  • Bispecific Checkpoint Inhibitor & Costimulator Antibodies
  • Bispecific CD47 Tumor Microenvironment (TME) Targeted Antibodies
  • Other Bispecific, Tumor Microenvironment (TME) Targeted Antibodies
  • Bispecific, Dual PD-1 & PD-L1 Checkpoint Inhibitor Antibodies
  • Bispecific, Dual PD-1/PD-L1 & CTLA-4 Checkpoint Inhibitor Antibodies
  • Bispecific, Dual PD-1 & LAG-3 Checkpoint Inhibitor Antibodies
  • Bispecific, Dual PD-L1/CTLA-4 & LAG-3 Checkpoint Inhibitor Antibodies
  • Bispecific, PD-1/PD-L1/CTLA-4 & TIM-3 or GITR Checkpoint Inhibitor Antibodies
  • Bispecific, Not Specified Immuno-Oncology Antibodies

5) Bispecific Tumor Associated Antigen (TAA) / Growth Factor Targeted Antibodies

  • Bispecific Her2-Targeted Antibodies
  • Bispecific VEGF-Targeted Antibodies
  • Other Bispecific TAA-Targeted Antibodies

6) Bispecific Antibodies for Non-Cancer Indications

  • Bispecific Inflammatory & Autoimmune Disease Antibodies
  • Bispecific Cardiometabolic Antibodies
  • Bispecific Ophthalmic Disease Antibodies
  • Bispecific Neurologic Disease Antibodies
  • Bispecific Infectious Disease Antibodies
  • Bispecific Antibodies For Targeted Delivery